Pharmaceuticals

Biotechnology

When There Is No Approved Treatment: The Race to Deploy Mapp Bio's Experimental Ebola Antibody

The WHO has declared the Bundibugyo Ebola outbreak a global health emergency. With no approved treatments, the US government has turned to a small San Diego biotech and its experimental antibody MBP134. The story reveals a structural gap in how the world prepares for infectious disease.

Pharmaceuticals

The Hormone Nobody Talked About: How Baxfendy Just Opened a New Front in the War on Hypertension

AstraZeneca's Baxfendy (baxdrostat) is the first aldosterone synthase inhibitor approved by the FDA, offering a fundamentally new approach to treating resistant hypertension in the 23 million Americans whose blood pressure remains uncontrolled despite multiple medications.

Biotechnology

Forty Years in the Making: How Three Competing Technologies Are Finally Challenging Alpha-1 Antitrypsin Deficiency

Three competing technologies—from Sanofi, Wave Life Sciences, and Beam Therapeutics—are finally challenging Alpha-1 Antitrypsin Deficiency after four decades of limited treatment options.

Biotechnology

The p-Value That Wasn't: What Regeneron's Fianlimab Miss Reveals About the Limits of Dual Checkpoint Blockade in Melanoma

Regeneron's Phase 3 HARMONY trial of fianlimab plus cemiplimab missed statistical significance in melanoma despite a 5.1-month PFS improvement. What the p-value of 0.0627 reveals about dual checkpoint blockade.

Biotechnology

The Cisplatin Gap Closes: AstraZeneca's VOLGA Trial Rewrites the Standard of Care for Bladder Cancer

AstraZeneca's VOLGA Phase 3 trial delivers a statistically significant overall survival benefit for cisplatin-ineligible muscle-invasive bladder cancer patients, marking a turning point for a population that has long been underserved by perioperative treatment options.

Policy

After Makary: What the FDA's Leadership Vacuum Means for Drug Development

Marty Makary's sudden resignation as FDA commissioner leaves the pharmaceutical industry facing regulatory uncertainty at a critical moment for biotech recovery.

Pharmaceuticals

The Pill That Changed Everything: FDA Approves First All-Oral AML Regimen for Elderly Patients

The FDA approves Inqovi in combination with venetoclax as the first all-oral treatment for elderly patients with newly diagnosed AML, eliminating the need for frequent infusion center visits.

Biotechnology

The Promise That Couldn't Scale: What Sarepta's Elevidys Decline Reveals About Gene Therapy's Commercial Ceiling

Sarepta's Elevidys gene therapy beats revenue estimates but faces declining sales, revealing the gap between clinical promise and commercial durability in the gene therapy sector.

Biotechnology

No Antibody, No Problem: How argenx Just Rewrote the Rules for Myasthenia Gravis Treatment

argenx's VYVGART receives FDA approval for all generalized myasthenia gravis patients regardless of serotype, including the triple seronegative population previously excluded from treatment options.

Biotechnology

Bayer's $2.45 Billion Bet on Blindness: What the Perfuse Deal Reveals About the Next Frontier in Eye Disease

Bayer's $2.45 billion acquisition of Perfuse Therapeutics signals a strategic shift in ophthalmology toward disease-modifying treatments that could reverse vision loss in glaucoma and diabetic retinopathy—conditions affecting over 200 million people worldwide.

Biotechnology

The $10 Million Drug That Could Be Worth Billions: How Celcuity's Gedatolisib Just Rewrote the Breast Cancer Playbook

In 2021, Pfizer sold a drug candidate for $10 million upfront. This week, that same drug delivered a Phase 3 win that could reshape the treatment of the most common form of breast cancer and generate more than $2 billion in annual sales.

Biotechnology

The Immune Reset Bet: Why UCB Just Paid $2.2 Billion for a T-Cell Engager

UCB's $2.2 billion acquisition of Candid Therapeutics signals a fundamental shift in autoimmune treatment strategy. T-cell engagers could reshape immunology the way CAR-T transformed oncology.